SI3607962T1 - Angiotenzin ii samostojno ali v kombinaciji za zdravljenje hipotenzije - Google Patents

Angiotenzin ii samostojno ali v kombinaciji za zdravljenje hipotenzije

Info

Publication number
SI3607962T1
SI3607962T1 SI201432120T SI201432120T SI3607962T1 SI 3607962 T1 SI3607962 T1 SI 3607962T1 SI 201432120 T SI201432120 T SI 201432120T SI 201432120 T SI201432120 T SI 201432120T SI 3607962 T1 SI3607962 T1 SI 3607962T1
Authority
SI
Slovenia
Prior art keywords
hypotension
angiotensin
alone
treatment
combination
Prior art date
Application number
SI201432120T
Other languages
English (en)
Slovenian (sl)
Inventor
Lakhmir Chawla
Original Assignee
The George Washington University, A Congressionally Chartered Not-For-Profit Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53367119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3607962(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by The George Washington University, A Congressionally Chartered Not-For-Profit Corporation filed Critical The George Washington University, A Congressionally Chartered Not-For-Profit Corporation
Publication of SI3607962T1 publication Critical patent/SI3607962T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/085—Angiotensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI201432120T 2013-12-18 2014-12-18 Angiotenzin ii samostojno ali v kombinaciji za zdravljenje hipotenzije SI3607962T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361917576P 2013-12-18 2013-12-18
US201461955706P 2014-03-19 2014-03-19
EP19197866.7A EP3607962B1 (en) 2013-12-18 2014-12-18 Angiotensin ii alone or in combination for the treatment of hypotension

Publications (1)

Publication Number Publication Date
SI3607962T1 true SI3607962T1 (sl) 2026-02-27

Family

ID=53367119

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201432120T SI3607962T1 (sl) 2013-12-18 2014-12-18 Angiotenzin ii samostojno ali v kombinaciji za zdravljenje hipotenzije
SI201431450T SI2986308T1 (sl) 2013-12-18 2014-12-18 Angiotenzin II v kombinaciji za zdravljenje hipotenzije

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201431450T SI2986308T1 (sl) 2013-12-18 2014-12-18 Angiotenzin II v kombinaciji za zdravljenje hipotenzije

Country Status (25)

Country Link
US (7) US9220745B2 (enExample)
EP (2) EP2986308B1 (enExample)
JP (4) JP6824739B2 (enExample)
KR (4) KR20220028125A (enExample)
CN (4) CN106061493A (enExample)
AU (3) AU2014364528C1 (enExample)
BR (1) BR112016013961A2 (enExample)
CA (1) CA2933601A1 (enExample)
CY (1) CY1122604T1 (enExample)
DK (2) DK2986308T3 (enExample)
EA (1) EA037823B1 (enExample)
ES (2) ES2771749T3 (enExample)
FI (1) FI3607962T3 (enExample)
HR (2) HRP20200009T1 (enExample)
HU (1) HUE047062T2 (enExample)
IL (1) IL246162B (enExample)
LT (2) LT2986308T (enExample)
MX (2) MX380968B (enExample)
NZ (1) NZ721089A (enExample)
PL (2) PL3607962T3 (enExample)
PT (2) PT3607962T (enExample)
RS (2) RS59804B1 (enExample)
SI (2) SI3607962T1 (enExample)
SM (2) SMT202500427T1 (enExample)
WO (1) WO2015095535A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
LT2986308T (lt) 2013-12-18 2020-03-25 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Angiotenzino ii derinys hipotenzijai gydyti
MX2017000306A (es) * 2014-07-08 2017-07-10 La Jolla Pharma Co Metodos para tratar hipotension.
WO2016153558A1 (en) 2015-03-20 2016-09-29 Atkinson Arthur J Use of angiotensin ii (aii) receptor agonists to prevent or reduce hemodialysis-associated skeletal muscle cramps
AU2017205168A1 (en) * 2016-01-07 2018-08-16 La Jolla Pharma, Llc Methods for administering angiotensin II
KR20180108630A (ko) * 2016-01-07 2018-10-04 라 졸라 파마슈티칼 컴파니 혈관수축제의 투여 방법
WO2018191678A1 (en) * 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
TW201927331A (zh) * 2017-12-15 2019-07-16 美商拉荷亞製藥公司 血管收縮素組合物及與其相關之方法
US20250366467A1 (en) * 2022-06-15 2025-12-04 Virginia Commonwealth University Methods for fluid resuscitation of an organ donor
WO2024129057A1 (en) * 2022-12-12 2024-06-20 Proletariat Therapeutics, Inc. Methods of treating cardiac injury

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU181008B (en) 1980-01-18 1983-05-30 Richter Gedeon Vegyeszet Process for producing angiotenzin-ii analogues of antagonistic activity containing sarcosyl-group at the 1-positon,and an alpha-hydroxy-carboxylic acid at the 8-position
US5216025A (en) * 1989-09-13 1993-06-01 Board Of Regents, The University Of Texas System Nitric oxide synthesis inhibitors for potentiating the action of pressor agents in certain hypotensive patients
US5444067A (en) 1993-08-30 1995-08-22 Merck & Co., Inc. Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety
CA2448051A1 (en) 2001-06-04 2002-12-12 Human Genome Sciences, Inc. Methods and compositions for modulating ace-2 activity
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
US7785566B2 (en) 2003-11-06 2010-08-31 Ge Healthcare, Inc. Pharmaceutical compounds
NO20034952D0 (no) 2003-11-06 2003-11-06 Amersham Health As Farmasöytiske forbindelser
FR2880807B1 (fr) * 2005-01-19 2007-04-13 Aguettant Sa Lab Composition pharmaceutique injectable
ATE507243T1 (de) 2005-09-29 2011-05-15 Fibrogen Inc Verfahren zur senkung des blutdrucks
CN101351215A (zh) * 2005-12-30 2009-01-21 霍华德·弗洛里实验生理学及医学研究所 治疗方法
CA2655144A1 (en) 2006-06-15 2007-12-21 Gilead Colorado, Inc. Antihypertensive therapy method
WO2008130217A1 (en) * 2006-08-08 2008-10-30 Applied Nanosystems B.V. Cyclic angiotensin analogs
WO2008059062A1 (en) 2006-11-17 2008-05-22 Da Volterra Colonic delivery using zn/pectin beads with a eudragit coating.
WO2009009907A1 (en) * 2007-07-18 2009-01-22 The University Of British Columbia Use of vasopressin-receptor agonists for the treatment of septic shock
EP2161030A1 (en) * 2008-09-09 2010-03-10 Rijksuniversiteit te Groningen Oxytocin formulations and uses thereof
MX2011005672A (es) 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
US9572856B2 (en) 2009-12-16 2017-02-21 The George Washington University a Congressionally Chartered Not-for-Profit Corporation Method of treating low blood pressure
FR2959414B1 (fr) * 2010-04-30 2016-01-08 Luc Quintin Combinaison de molecules aux fins de traitement d'hypotension survenant au cours du choc septique, cardiogenique, ou anaphylactique refractaire, ou hemorragique terminal, apres correction de la volemie et de l'etat de mal asthmatique refractaire
KR20130026504A (ko) 2010-07-14 2013-03-13 큠버랜드 에멀징 테크놀로지스 아이앤씨 트롬복산-a2 수용체 길항제를 이용한 간신증후군 및 간성뇌증의 치료방법
CN105592855A (zh) 2013-04-26 2016-05-18 拉卓拉药物公司 用于治疗肾衰竭的组合物和方法
LT2986308T (lt) 2013-12-18 2020-03-25 The George Washington University, A Congressionally Chartered Not-For-Profit Corporation Angiotenzino ii derinys hipotenzijai gydyti
US20150286797A1 (en) 2014-04-02 2015-10-08 David R. Ratto System and method for administering medication
MX2017000306A (es) 2014-07-08 2017-07-10 La Jolla Pharma Co Metodos para tratar hipotension.
KR20180108630A (ko) 2016-01-07 2018-10-04 라 졸라 파마슈티칼 컴파니 혈관수축제의 투여 방법
AU2017205168A1 (en) 2016-01-07 2018-08-16 La Jolla Pharma, Llc Methods for administering angiotensin II
WO2018191678A1 (en) 2017-04-14 2018-10-18 La Jolla Pharmaceutical Company Methods for administering angiotensin ii
TW201927331A (zh) 2017-12-15 2019-07-16 美商拉荷亞製藥公司 血管收縮素組合物及與其相關之方法

Also Published As

Publication number Publication date
JP2025114753A (ja) 2025-08-05
EP2986308A1 (en) 2016-02-24
AU2014364528A1 (en) 2016-06-30
PL3607962T3 (pl) 2026-03-09
ES3055611T3 (en) 2026-02-13
EP3607962B1 (en) 2025-08-13
LT2986308T (lt) 2020-03-25
CN119700926A (zh) 2025-03-28
MX2020011190A (es) 2020-11-13
KR20240154702A (ko) 2024-10-25
EP3607962A1 (en) 2020-02-12
IL246162B (en) 2020-03-31
US10765722B2 (en) 2020-09-08
US20190328827A1 (en) 2019-10-31
ES2771749T3 (es) 2020-07-07
US20190070250A1 (en) 2019-03-07
KR20220028125A (ko) 2022-03-08
US11096983B2 (en) 2021-08-24
US20230226141A1 (en) 2023-07-20
JP6824739B2 (ja) 2021-02-03
AU2024219851A1 (en) 2024-10-10
US10493124B2 (en) 2019-12-03
KR20230051721A (ko) 2023-04-18
JP2022137224A (ja) 2022-09-21
AU2014364528A9 (en) 2016-07-28
HRP20251406T1 (hr) 2026-02-27
PL2986308T3 (pl) 2020-05-18
FI3607962T3 (fi) 2025-11-24
LT3607962T (lt) 2026-01-12
JP7175506B2 (ja) 2022-11-21
EP2986308B1 (en) 2019-10-16
CN112546197A (zh) 2021-03-26
CA2933601A1 (en) 2015-06-25
EA037823B1 (ru) 2021-05-25
BR112016013961A2 (pt) 2017-10-10
MX2016008108A (es) 2017-03-09
MX380968B (es) 2025-03-12
SMT202500427T1 (it) 2026-01-12
AU2014364528C1 (en) 2021-01-07
JP2017501154A (ja) 2017-01-12
DK3607962T3 (da) 2025-11-17
JP2019214610A (ja) 2019-12-19
WO2015095535A1 (en) 2015-06-25
PT3607962T (pt) 2025-11-18
EA201691258A1 (ru) 2016-11-30
US11559559B2 (en) 2023-01-24
CY1122604T1 (el) 2021-03-12
CN111920939A (zh) 2020-11-13
EP2986308A4 (en) 2017-01-11
DK2986308T3 (en) 2020-01-27
US20150164980A1 (en) 2015-06-18
US20180193407A1 (en) 2018-07-12
RS59804B1 (sr) 2020-02-28
CN106061493A (zh) 2016-10-26
US10028995B2 (en) 2018-07-24
US20160129072A1 (en) 2016-05-12
US9220745B2 (en) 2015-12-29
SMT202000018T1 (it) 2020-03-13
RS67626B1 (sr) 2026-02-27
NZ721089A (en) 2022-10-28
KR20160117437A (ko) 2016-10-10
SI2986308T1 (sl) 2020-03-31
HRP20200009T1 (hr) 2020-03-20
US20220047669A1 (en) 2022-02-17
PT2986308T (pt) 2020-01-21
KR102399383B1 (ko) 2022-05-19
HUE047062T2 (hu) 2020-04-28
AU2014364528B2 (en) 2020-08-27
WO2015095535A9 (en) 2016-07-14
AU2020277230A1 (en) 2020-12-24
IL246162A0 (en) 2016-07-31

Similar Documents

Publication Publication Date Title
GB2516814B (en) Use of phytocannabinoids for increasing radiosensitivity in the treatment of cancer
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
GB201321738D0 (en) Therapeutic Agents
IL246162B (en) Angiotensin II, alone or in combination, to treat low blood pressure
GB201321736D0 (en) Therapeutic agents
IL244014A0 (en) Combined therapy for the treatment of glioblastoma
GB201321729D0 (en) Therapeutic agents
GB201321728D0 (en) Therapeutic agents
GB201321733D0 (en) Therapeutic agents
GB201321739D0 (en) Therapeutic agents
GB201321730D0 (en) Therapeutic agents
GB201321732D0 (en) Therapeutic agents
GB201321734D0 (en) Therapeutic Agents
GB201321737D0 (en) Therapeutic Agents
GB201321735D0 (en) Therapeutic Agents
GB201304872D0 (en) Treatment
GB201321731D0 (en) Therapeutic agents
GB201317960D0 (en) Water treatment
GB201302839D0 (en) Water Treatment
GB201307310D0 (en) Treatment
ZA201604412B (en) Water treatment
GB201416965D0 (en) Water treatment
GB201313159D0 (en) Finishing Treatment
GB201321115D0 (en) Treatment
GB201309238D0 (en) Treatment